Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -585.97M | -608.97M | -574.97M | -579.62M | -532.72M |
| Total Depreciation and Amortization | 33.39M | 34.39M | 35.39M | 36.14M | 36.29M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.88M | 95.88M | 96.88M | 99.04M | 100.45M |
| Change in Net Operating Assets | -24.55M | -18.55M | -23.55M | -1.31M | -25.34M |
| Cash from Operations | -485.25M | -497.25M | -466.25M | -445.74M | -421.31M |
| Capital Expenditure | -4.22M | -6.22M | -6.22M | -5.44M | -5.78M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 44.15M | 73.15M | 242.15M | 416.13M | 23.78M |
| Cash from Investing | 39.94M | 66.94M | 235.94M | 410.69M | 18.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.19M | 86.19M | 86.19M | 86.95M | 91.12M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 392.00M | 392.00M | 392.00M | 0.00 | 7.00M |
| Cash from Financing | 397.19M | 478.19M | 478.35M | 87.10M | 98.28M |
| Foreign Exchange rate Adjustments | -362.00K | 2.64M | 4.64M | 3.35M | 4.33M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.49M | 50.52M | 252.52M | 55.24M | -300.86M |